Latest News & Features
Big Pharma
Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel. 25 January 2022
Big Pharma
Effective support and guidance can achieve greater diversity in life sciences, say general counsel from Bristol Myers Squibb, AstraZeneca, The Chemours Company and Eli Lilly. 25 January 2022
Big Pharma
PeriRx has been hit with sanctions over its conduct after its breach of licensing suit failed in a patent licensing dispute against the University of California. 24 January 2022
Americas
The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule. 20 January 2022
Americas
Gilead Sciences has sued an array of pharmaceutical suppliers and distributors accusing them of forming a counterfeiting network and allegedly selling fake versions of its HIV medications. 20 January 2022
Biotechnology
While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird. 20 January 2022
Americas
Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description. 18 January 2022
Americas
The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma. 18 January 2022
Americas
Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid. 17 January 2022
Medtech
Arthrex says that it did not get the “remedy” ordered by the US Supreme Court in its landmark case against Smith & Nephew. 13 January 2022